Rob Finizio

Rob Finizio is a Co-Founder and Managing Partner of MintPharma Capital leveraging over 30 years of experience building significant shareholder returns in both public and private pharmaceutical and medical device companies.

Rob co-founded CareFusion, the market leader in medication patient safety in 2001, which he sold to Cardinal Health (CAH) in 2006.

After CareFusion, Rob co-founded TherapeuticsMD (TXMD) in 2008. As the CEO and Vice Chairman, Rob developed TXMD from a start-up to the market leader in women’s health pharmaceutical development. TXMD is the first and only women’s health pharmaceutical company to have three new drugs approved in a single year (2018). In 2013, Rob took TXMD public on the New York Stock Exchange and achieved a market capitalization of well over a billion dollars. During his tenure at TXMD, Rob raised more than $1 Billion dollars through public equity and debt.

Rob currently serves as a board member and Executive Director of PleoPharma, Myosin Therapeutics and Zyversa (ZVSA, NASDAQ),. PleoPharma is an innovative pharmaceutical company endeavoring to develop the first FDA-approved drug to treat Cannabis Withdrawal as well as other addiction therapies where no FDA-approved treatments exist. Myosin Therapeutics (a spin-out from Scripps Research in Jupiter, FL) is leveraging a pioneering approach to treating cancer by targeting non-muscle Myosin nanomotors to inhibit movement and growth of cancer cells.

Rob is involved with two non-profits, Chairman of Bio-Florida, and a Board Member for the Palm Beach County Sheriff’s Office Foundation. Rob graduated from the University of Miami with a Bachelor of Arts degree in Psychology and taught English in Osaka, Japan after graduation.